Processa Pharmaceuticals, Inc.
PCSAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeProcessa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company carries a $5.8M market cap, placing it firmly in the micro-cap category. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Market Cap
$5.8M
Beta
0.97
P/E (TTM)
3.17
P/E (Fwd)
-0.55
EPS (TTM)
$0.65
EPS (Fwd)
$-3.75
ROE
-464.2%
ROA
-156.8%
Cash
$196,325
Total Debt
$0
Free CF
-$8.7M
52W Change
-54.2%
Annual Financials
Cash vs Debt
Where PCSA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PCSA finished 14.63% below its 150-day moving average ($2.46) and 31.15% below its 200-day moving average ($3.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PCSA overbought or oversold?
At the September 3, 2026 close, PCSA's RSI(14) was 25.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Processa Pharmaceuticals, Inc. reports $196K in cash and $0 in total debt. The company is burning cash, with free cash flow at -$8.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -464.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PCSA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.